Answers are grounded in this paper and cite their sources.
Introduction: The Omnipod® 5 Automated Insulin Delivery (AID) System is the first wearable, on-body, tubeless AID system in the United States. Clinical trials have demonstrated hemoglobin A1C (HbA1c) improvements with Omnipod 5 use. The aim of the study was to evaluate HbA1c changes after initiating Omnipod 5 in a real-world setting. Methods: This retrospective study utilized commercial and Medicare Advantage with Part D enrollees’ claims data from the Optum Research Database between August 1, 2021, and December 31, 2023. The study included individuals diagnosed with type 1 diabetes (T1D) or type 2 diabetes (T2D) who initiated Omnipod 5. Participants were required to have continuous enrollment for 12 months pre- and post-initiation and at least two medical claims for diabetes during these periods. Demographic and clinical characteristics were measured at the index date, and HbA1c levels were compared pre- and post-initiation of Omnipod 5. Results: The final sample included 2,504 users, with 792 having pre- and post-initiation HbA1c results. The mean age was 54 years; 48% were enrolled in Medicare Advantage, 90% had prior continuous glucose monitoring, and 64% had prior pump therapy. A mean reduction in HbA1c of 0.4% was observed ( P < 0.001); mean reductions were 0.4% and 0.5% among those with type 1 and type 2 diabetes, respectively. Among 135 users with pre-initiation HbA1c levels ≥9%, a reduction of 1.4% was noted ( P < 0.001). Pre-initiation, 31% achieved the American Diabetes Association (ADA) target of <7% compared to 44% post-initiation (increase of 13%; P < 0.001). For the Healthcare Effectiveness Data and Information Set (HEDIS) target of <8%, 62% of individuals achieved the target pre-initiation compared to 78% post-initiation (increase of 16%; P < 0.001). Conclusions: In a real-world setting, Omnipod 5 was associated with reduced HbA1c and an increased proportion of individuals achieving ADA and HEDIS glycemic targets.
No takes yet. Share an insight, caveat, or question.
Levy et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: